Covance Extends Lab Services in Asia Pacific

Covance (Princeton, NJ, USA) has increased its laboratory testing capabilities in the Asia Pacific region. The company has announced several new developments in the region, has signed two new contracts with large Japanese firms, has achieved regulatory accreditation for two of its main laboratories, and has expanded its lab testing and kit production facilities.

"With the combination of our broad, expanded portfolio of laboratory testing capabilities, CAP [College of American Pathologists] certifications in Singapore and China, and the extension of our global Virtual Central Laboratory capabilities in Japan, Covance continues to provide the industry's most comprehensive and flexible clinical trial laboratory service solutions to the growing numbers of sponsors conducting clinical studies in the Asia Pacific Rim.” said John Marolf, general manager of Covance Central Laboratory Services, Asia Pacific and Southern Africa.

In Singapore and Sydney, Covance laboratories provide routine chemistry, hematology, urinalysis and serology, and have recently been expanded to provide additional laboratory testing services. In both the Chinese and Singapore laboratories, the company has expanded its special testing services in the areas of microbiology, immunology, special chemistry, and quantitative polymerase chain reaction (PCR) testing for the human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV).

The Central Laboratory Services of Covance have exclusive, dedicated laboratory operations in the United States, Switzerland, Singapore, and Australia, with a dedicated operating agreement in Shanghai (China) with the Huashan Hospital laboratory. With the announcement of CAP certification within the Singapore and Huashan Hospital laboratories, Covance now has a network of certified laboratory testing facilities around the world.



Related Links:
Covance